ANAVEX LIFE SCIENCES CORP (AVXL)
Health Care · Biotechnology · NASDAQ
A clinical-stage biopharma company developing precision medicine treatments for Alzheimer's, Parkinson's, and rare CNS diseases by targeting the sigma-1 receptor.
What ANAVEX LIFE SCIENCES CORP does
Anavex Life Sciences is a clinical-stage biopharmaceutical company focused on developing precision medicine therapeutics for central nervous system (CNS) diseases. The company utilizes genomic data and biomarker identification to advance a pipeline of candidates, primarily targeting sigma-1 receptor (SIGMAR1) activation to restore cellular homeostasis in neurodegenerative and neurodevelopmental conditions. Its lead development programs include blarcamesine (ANAVEX 2-73) and ANAVEX 3-71, targeting indications such as Alzheimer’s disease, Parkinson’s disease, Rett syndrome, and other rare CNS disorders.
Themes: CNS disorders / neurology, Alzheimer's disease drug development, Parkinson's disease drug development, rare disease therapeutics, precision medicine, sigma-1 receptor modulation
Fundamentals
- Price$3.24 as of 2026-08-21 close
- Market cap$300M as of 2026-08-21
- 1-year return-66.1% 2025-08-21 close $9.55 → 2026-08-21 close $3.24
- P/En/a earnings data not available
- ROE-38.8% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Beta1.17 as of 2026-08-24
- Last reported earnings2026-07-30 SEC EDGAR Form 8-K (Item 2.02)
How AVXL compares in its sector
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How ANAVEX LIFE SCIENCES CORP looks technically
ANAVEX LIFE SCIENCES CORP (AVXL) is trading 11.9% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 211 trading days ago — a "death cross", a bearish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 28, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 58, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 2 trading days ago (its momentum flipped negative). It made a new 20-day high about 9 trading days ago. It is 68.8% below its highest point of the past year.
Trend
7
| Distance from the 200-day | it is trading 11.9% below its 200-day average, the long-term trend line — a long-term downtrend | -11.9% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $2.77 | $2.77 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $3.68 | $3.68 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 9 calendar days ago — the swings before that are what the structure reading is measured on | 9 sessions |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 211 trading days ago — a "death cross", a bearish long-term signal | 211 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 28, with buyers in control | 27.5 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 58, neither overbought (above 70) nor oversold (below 30) | 57.6 |
|---|---|---|
| Position in its 14-day range | it is trading around the middle of its 14-day range ($2.94 to $3.57) — its "stochastic" reading is 48 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 48.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 2 trading days ago (its momentum flipped negative) | 2 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $10.40 | $10.40 |
|---|---|---|
| From the 52-week high | it is 68.8% below its 52-week high (its highest price of the past year) | -68.8% |
| Above the 52-week low | it is 43.7% above its 52-week low (its lowest price of the past year) | +43.7% |
| Below the 52-week high | it is 68.8% below its highest point of the past year | 68.8% |
| Since a 20-day breakout | it made a new 20-day high about 9 trading days ago | 9 sessions |
| Since a 55-day breakout | it made a new 55-day high about 9 trading days ago | 9 sessions |
| All-time high | its highest closing price on record is $31.50 (set on 2021-06-28) | $31.50 |
| Given back of the 52-week move | over the past year its closes ranged ($2.34 to $10.26), and it has recovered only a small part of its fall from last year’s high — 11% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $7.23 to $7.49. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 11.4% |
| From the all-time high | it is 89.7% below its all-time high | -89.7% |
| Nearest price level | it is trading 8.0% below a resistance level at $3.50 — a price it turned at twice since 2026-01-02, most recently on 2026-05-04. Since 2024-08-21 it has 2 such levels below the current price and 13 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +8.0% |
| All-time low | its lowest closing price on record is $0.6 (set on 2014-12-01) | $0.6 |
| Above the all-time low | it is 440.0% above its all-time low | +440.0% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 75% of it) | 75th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.169 between its high and its low — about 5.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.169 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $2.47 and $3.72 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $2.47 – $3.10 – $3.72 |
| Typical daily range (% of price) | its price moves about 5.2% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.2% |
| Stretch from the 200-day average | it is trading 2.6 daily ranges below its 200-day average price (11.9% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.6 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.52× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
1
| Since a hammer | 5 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 5 sessions ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-08-21 1.3% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +1.3% |
|---|---|---|
| Gap filled | a 2.8% gap down opened on 2026-07-27 has been "filled" 19 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 19 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 24.5 percentage points (the stock gained 26.8% while the market gained 2.3%) | +24.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 16.5 percentage points (the stock gained 19.6% while the market gained 3.1%) | +16.5% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 32.4 percentage points (the stock lost 21.4% while the market gained 11.1%) | -32.4% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 86.6 percentage points (the stock lost 66.1% while the market gained 20.5%) | -86.5% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, MACD momentum is negative, lagging the market over 6 months — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 12% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-15 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thick, spanning 10.9% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | +11.7% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 5% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $3.43 — a volume-weighted average of daily closes over 159 sessions, not a true tick-by-tick VWAP. | -5.4% |
|---|
Price levels it has turned at before
AVXL last closed at $3.24 on 2026-08-21. Since 2024-08-21 it has turned at 2 prices below its last close and 13 above; the 2 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $3.50 | Resistance | 8.0% above the last close | turned there twice · 2026-01-02 to 2026-05-04 |
| $3.56 | Resistance | 10.0% above the last close | turned there twice · 2025-12-22 to 2026-08-12 |
| $2.79 | Support | 13.7% below the last close | turned there twice · 2026-06-22 to 2026-07-08 |
| $3.75 | Resistance | 15.7% above the last close | turned there twice · 2026-02-11 to 2026-04-20 |
| $2.62 | Support | 19.1% below the last close | turned there twice · 2026-03-25 to 2026-05-22 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · MACD just crossed bearish (12/26/9) · in a strong, established uptrend (ADX) · lagging the market · Trading above the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$20.00 range $20.00 – $20.00
Analyst estimates, as of 2026-08-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for AVXL
- Consensus EPS estimate-$0.08 next reporting period, as of 2026-08-17
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["High dependence on the clinical success and regulatory approval of lead candidates such as blarcamesine, with no products currently approved for commercial sale.","Significant recurring operating losses and reliance on continued capital raises to fund ongoing research and development operations.","Uncertainty regarding the clinical efficacy of targeting SIGMAR1 receptors and the potential for failure in late-stage clinical trials."]
What changed in the latest 10-Q
AI-assisted comparison of AVXL's 10-Q filed 2026-02-09 against the prior one filed 2025-08-12.
Management's Discussion & Analysis (MD&A)
- Added:
- Added reference to 'EMA' in forward-looking statements list (newer filing, 2026-02-09)
- Added 'secure regulatory approval' language in forward-looking statements (newer filing, 2026-02-09)
- Removed:
- Removed bullet point 'our ability to comply with the maintenance requirements of the government patent agencies' (older filing, 2025-08-12)
- Removed bullet point 'our ability to protect our intellectual property rights throughout the world' (older filing, 2025-08-12)
- Removed bullet point 'competition' as standalone item (older filing, 2025-08-12)
- Removed reference to 'and other regulatory authorities' in forward-looking statements basis text (older filing, 2025-08-12)
- Removed reference to 'and the risks described in Part II, Item 1A of this Quarterly Report on Form 10-Q' (older filing, 2025-08-12)
- Reworded:
- Changed '10-K filed with the Securities and Exchange Commission on December 23, 2024' to 'Annual Report on Form 10-K filed with the Securities and Exchange Commission on November 25, 2025' (newer filing reflects updated filing date)
- Changed 'the FDA and other regulatory authorities' to 'the FDA, EMA and other regulatory authorities' (newer filing adds specific EMA reference)
- Changed 'or EMA' to '("EMA")' and 'or MAA' to '("MAA")' in forward-looking statements list (newer filing adds parenthetical abbreviation formatting)
- Replaced separate bullet point listing 'competition' with phrase 'our ability to compete in the highly competitive biotechnology and pharmaceutical industries' integrated into forward-looking statements (newer filing, 2026-02-09)
- Notes:
- Both filings appear truncated at the end of the Overview and Strategy section; comparison is limited to the portions provided
- Page numbering differs between filings (page 19-20 in newer vs. page 20-21 in older), suggesting layout changes unrelated to content modifications
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for AVXL — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding AVXL as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 13,578,976
- Reported value $41,687,455
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
AVXL had 14,426,670 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
AVXL had 15.6% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 14.43 days to cover at the same settlement.
- Reported short interest (shares) 14,426,670
- Short interest (% of shares outstanding) 15.6%
- Prior settlement (shares) 14,140,060
- Reported change 2.03%
- Days to cover (reported) 14.43
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare AVXL vs…
ANAVEX LIFE SCIENCES CORP is found in…
Frequently asked questions
What does ANAVEX LIFE SCIENCES CORP (AVXL) do?
Anavex Life Sciences is a clinical-stage biopharmaceutical company focused on developing precision medicine therapeutics for central nervous system (CNS) diseases. The company utilizes genomic data and biomarker identification to advance a pipeline of candidates, primarily targeting sigma-1 receptor (SIGMAR1) activation to restore cellular homeostasis in neurodegenerative and neurodevelopmental conditions.
What sector is ANAVEX LIFE SCIENCES CORP (AVXL) in?
ANAVEX LIFE SCIENCES CORP (AVXL) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are ANAVEX LIFE SCIENCES CORP's (AVXL) competitors?
Notable peers of ANAVEX LIFE SCIENCES CORP (AVXL) include Biogen, Eli Lilly, Roche, Acadia Pharmaceuticals and Sage Therapeutics. This peer set is informational only — not financial advice.
Is ANAVEX LIFE SCIENCES CORP (AVXL) overbought or oversold right now?
ANAVEX LIFE SCIENCES CORP (AVXL) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 58, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on AVXL come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.